Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

InterMune IPF drug enters Phase III

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

InterMune commences enrollment of Phase III CAPACITY program evaluating pirfenidone for treatment of idiopathic pulmonary fibrosis (IPF), the firm says April 27. The dual-trial program "will advance relatively quickly and conclude toward the end of 2007," CEO Dan Welch states. Top-line data are expected in early 2009. InterMune finalized the studies' designs with FDA last fall; the company has pointed to CAPACITY as the first IPF program to utilize lung function as the primary endpoint (1Pharmaceutical Approvals Monthly November 2005, p. 6). Pirfenidone is a small molecule p38-gamma inhibitor. Other firms developing IPF treatments include Actelion, CoTherix and Novartis...

You may also be interested in...



InterMune Plans Pirfenidone Pulmonary Fibrosis Phase III Study In 2006

InterMune's pivotal trials of pirfenidone will be the first Phase III studies of an idiopathic pulmonary fibrosis drug to use the primary endpoint of lung function as measured by change in forced vital capacity

DJO Thinks Trilliant Is Brilliant, Announces Acquisition

DJO Global will buy Trilliant Surgical to further its ongoing expansion into the US foot and ankle market.

Legend Biotech CEO Ying Huang On Moving Fast In the BCMA CAR-T Race

Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.

Topics

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel